Strategic Funding Psilera has secured multi-stage funding including an oversubscribed $8.8M Seed extension in 2026 and NIH grant support for IND-enabling studies, signaling strong investor confidence and potential for continued collaboration and co-development opportunities.

Clinical Momentum Recent appointment of a Vice President of Clinical Development and upcoming Phase 1 trial indicate advancing clinical programs in neurology and addiction, presenting opportunities to explore partnerships in clinical development services, CRO engagement, and investigator collaborations.

Platform Collaboration Launch of a novel synthetic platform for neuroplastogens suggests openness to collaboration on platform-enabled discovery programs, licensing of platform tech, and joint research agreements with pharma and biotech partners.

IP Licensing Existing IP licensing activity with atai Life Sciences and asset divestment actions imply a market for licensing, acquisition talks, or strategic alliances around neuropsychiatric compounds and related patent portfolios.

NIH Backing NIH grant funding for IND-enabling studies provides non-dilutive capital and validation, creating a pathway for government-funded collaborations, contract research, and early-access programs aligned with Psilera's drug development timeline.